Janice Cyr, in Ashland, ME - Speech-Language Pathologist

Janice Cyr, is a Speech-language Pathologist based in Ashland, Maine. Janice Cyr is licensed to practice in Maine (license number SP1004) and her current practice location is 180 Presque Isle Rd, Ashland, Maine. She can be reached at her office (for appointments etc.) via phone at (207) 435-3661.

NPI number for Janice Cyr is 1851606057 and her current mailing address is 180 Presque Isle Rd, Ashland, Maine. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1851606057.

Contact Information

	Janice Cyr,
	180 Presque Isle Rd, Ashland, ME 04732-0369
	(207) 435-3661
	Not Available

Healthcare Provider's Profile

Full Name	Janice Cyr
Gender	Female
Speciality	Speech-language Pathologist
Location	180 Presque Isle Rd, Ashland, Maine
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1851606057
Provider Enumeration Date: 08/11/2010
Last Update Date: 08/11/2010

Medical Identifiers

Medical identifiers for Janice Cyr such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1851606057	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	SP1004 (Maine)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Janice Cyr is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Janice Cyr, 180 Presque Isle Rd, Ashland, ME 04732-0369 Ph: () -	Janice Cyr, 180 Presque Isle Rd, Ashland, ME 04732-0369 Ph: (207) 435-3661

News Archive

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

Requests for organ donors must be tempered by a better understanding of cultural differences

In Canada, most organ donations come from people who have died, rather than from living donors. In western culture, there is a division between mind and body, he explains. Once the brain no longer functions, the corpse is no longer considered a true person - as highlighted by Descartes' philosophy, "I think, therefore, I am" - so organ donation is seen as acceptable. In addition, western society has been greatly influenced by the Christian belief in the spiritual value of non-reciprocal giving, says Bowman, making organ donation a gift of love and generosity.

Mercury associated with autoimmunity among women of childbearing age

One of the greatest risk factors for autoimmunity among women of childbearing age may be associated with exposure to mercury such as through seafood, a new University of Michigan study says.

Menopause supplement to bring body back into balance

Whitemark Homes, Inc., is pleased to announce a satisfaction guaranteed top selling product line by Ribbon Naturals Corp., complete system Menopause Solutions. A solution for women who are dissatisfied with the results they receive from common, everyday menopause supplements. Now there is a supplement for menopause that brings the body back into balance.

Janice Cyr, - Speech-Language Pathologist in Ashland, ME